Willard Patrick, McKay John, Yazbeck Victor
Virginia Commonwealth University, Department of Internal Medicine, Richmond, VA, United States of America.
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, United States of America.
Leuk Res Rep. 2021 Oct 24;16:100275. doi: 10.1016/j.lrr.2021.100275. eCollection 2021.
Monoclonal antibodies (mAb) for indolent non-Hodgkin's lymphoma (iNHL) including follicular and marginal zone lymphomas was a key therapeutic development that changed the natural history of these diseases. Rituximab, a chimeric anti-CD20 mAb, was the first immunotherapy ever used in cancer, and a current cornerstone of lymphoma therapies. Since, we saw development of humanized antibodies, next generations anti-CD20, mAbs targeting other markers on tumor cells (CD19 and CD22), its microenvironment (PD-1, CD47), antibody drug conjugates and bispecific T cell engagers. Given their activity, safety and specificity, mAbs are well poised to remain an essential therapeutic tool for iNHL and other malignancies.
用于惰性非霍奇金淋巴瘤（iNHL）（包括滤泡性淋巴瘤和边缘区淋巴瘤）的单克隆抗体（mAb）是一项关键的治疗进展，改变了这些疾病的自然病程。利妥昔单抗是一种嵌合抗CD20单克隆抗体，是有史以来第一种用于癌症治疗的免疫疗法，也是目前淋巴瘤治疗的基石。此后，我们见证了人源化抗体、新一代抗CD20抗体、靶向肿瘤细胞上其他标志物（CD19和CD22）及其微环境（PD-1、CD47）的单克隆抗体、抗体药物偶联物和双特异性T细胞衔接器的发展。鉴于其活性、安全性和特异性，单克隆抗体有望继续成为iNHL和其他恶性肿瘤的重要治疗工具。
